INTRODUCTION AND OBJECTIVES: Regionalization of cystectomy has been associated with improved outcomes but it may exacerbate geographic disparity by increasing travel distance. We sought to examine the association between travel distance to a highvolume cystectomy center and the probability of receiving a cystectomy among patients with muscle-invasive bladder cancer.
INTRODUCTION AND OBJECTIVES: Regionalization of cystectomy has been associated with improved outcomes but it may exacerbate geographic disparity by increasing travel distance. We sought to examine the association between travel distance to a highvolume cystectomy center and the probability of receiving a cystectomy among patients with muscle-invasive bladder cancer.
METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified patients diagnosed with non-metastatic muscle-invasive bladder cancer between 2004 and 2011. We further identified patient treatment (i.e, cystectomy, bladdersparing alternative) using the inpatient, outpatient, and carrier files. Patients were then grouped into quartiles according to travel distance to the nearest high-volume cystectomy center (<¼8, 9-22, 23-53, and >53 miles) . High-volume cystectomy centers included those with cystectomy volumes in the top quartile. The relationship between distance to a high-volume cystectomy center and treatment was assessed using a multivariable logistic regression model, adjusting for age, sex, race, comorbidity, marital status, county population, education level and median household income in ZIP code of residence, grade, and stage.
RESULTS: Among 5149 patients with non-metastatic muscleinvasive bladder cancer, 1998 (39%) underwent a radical cystectomy. The adjusted probability of receiving a cystectomy according to travel distance to a high-volume cystectomy center is summarized in Figure 1 . Compared to patients with a travel distance of 8 miles or less, those with a travel distance of 9-22 miles were less likely to receive a cystectomy (adjusted OR 0.79, 95% CI 0.66-0.96). However, this difference was mitigated in those with travel distances beyond 22 miles CONCLUSIONS: Our findings demonstrated a complex relationship between travel distances to a high-volume cystectomy center and the probability of receiving a radical cystectomy. While increasing distance decreased the likelihood of receiving a cystectomy for patients that live easily commutable distance, this disparity dissipated once the travel distance increased beyond 22 miles. INTRODUCTION AND OBJECTIVES: Painless gross hematuria (GH) is more likely to be associated urologic malignancy when compared to asymptomatic microscopic hematuria (AMH). However, the presence of either GH or AMH should prompt timely urologic evaluation in the absence of an obvious benign cause. The objective of our study is to evaluate whether presentation with GH or AMH was associated with a timely evaluation of patients that present with hematuria.
Source of Funding: none
METHODS: We performed a retrospective electronic health record (EHR) review of 190 consecutive patients who presented with new onset hematuria to a Veterans Affairs (VA) facility between 10/1/ 2011 and 12/31/2012. The VA 0 s EHR offers a comprehensive longitudinal picture of the patient 0 s diagnostic journey. We excluded patients who sought diagnostic care outside the institution (n¼22), patients with cystoscopy within 3 years prior (n¼9), patients with hematuria in the setting of active urinary tract infection (n¼3), and patients with terminal illness (n¼1). We collected detailed patient demographic data, medical/ psychiatric history, and times to diagnostic evaluation (abdominal imaging, urologic referral, and cystoscopy). We defined 0 delay 0 when diagnostic evaluation was not completed within 60 days from new onset hematuria. Multivariable logistic regression was performed to identify predictors of delay.
RESULTS: After exclusions, 76 (50.7%) patients were found to have new AMH and 74 (49.3%) new GH. Patients with GH had higher rate of urology referral than AMH (83.8% vs. 57.9%; p<0.001) and were more likely to undergo cystoscopy (75.7% vs. 50%; p¼0.001). Delays occurred in 65.8% of AMH patients and 64.9% of GH patients (p¼0.9). There was no difference in median days to abdominal imaging completion (33 vs. 27.5, p¼0.07), urology referral completion (30 vs. 23.5, p¼0.12), or time to cystoscopy completion (71.5 vs. 69, p¼0.73) between those presenting with AMH vs. GH. On multivariable logistic regression, there were no variables that predicted lack of action within 60 days. Within one year-post presentation, 1.3% of patients with AMH and 20.3% of patients with GH were found to have bladder neoplasms.
CONCLUSIONS: GH is approximately 20 times more likely to be associated with bladder cancer compared to AMH. Approximately 2/ 3 of patients with any hematuria were not evaluated within 60 days of presentation. Strategies to reduce these delays are warranted. Our previous study demonstrated predictable patient demographics and diagnoses associated with missed clinic appointments. The significant characteristics of our study included: age, new versus established patient, and patient diagnoses. This study aims to utilize our previous data to develop a model to predict patient missed clinic appointments.
Source of Funding: None
METHODS: Utilizing our previous data, logarithmic regression analysis was performed to formulate an equation to predict the probability of a patient missing their appointment. Variables included age, new versus established patient, and groupings of 27 patient diagnoses. Using this equation, a retrospective analysis of clinic patient data was performed for four full-time academic urologists over a six-month period comparing predicted versus actual missed visits. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1297
